Results 201 to 210 of about 86,631 (266)

Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. [PDF]

Cochrane Database Syst Rev
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF.   +4 more
europepmc   +1 more source

Incidence of Childhood Dilated Cardiomyopathy in Sweden From 1991 to 2019: A National Population‐Based Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim To study the incidence, survival, and mortality of dilated cardiomyopathy (DCM) in children in Sweden, 1991–2019. Methods Hospital records of 0–18‐year‐olds diagnosed with DCM over a 29‐year period were reviewed. The annual sex‐specific incidence rates of DCM were calculated as new disease cases, divided by the average Swedish same‐sex ...
Shalan Fadl, Stefan Särnblad, Tahir Taj, Håkan Wåhlander, Eva Fernlund, Jan Sunnegårdh   +5 more
wiley   +1 more source

Real-world efficacy of fimasartan vs. other angiotensin receptor blockers in combination with calcium channel blockers: a nationwide cohort study. [PDF]

Clin Hypertens
Lee H, Park CS, Kim B, Rhee TM, Lee H, Kim YJ, Han K, Kim HK.   +7 more
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis. [PDF]

Ann Med
Liu J, Chen W, Shao S, Chen Y, Wang H, Xi Y, Wang L.   +6 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers After Transcatheter Aortic Valve Replacement: A Meta-Analysis. [PDF]

JACC Adv
Bhat V, Kumar A, Kalra A.
europepmc   +1 more source

Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis. [PDF]

Indian J Nephrol
Devi D S K, Mary JJF, Mohan R, Gavlasova D, Kalaiselvan G, Kathiravan E, Foppiani JA, Saravanan V, Devi M A, Lin SJ.   +9 more
europepmc   +1 more source

ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock. [PDF]

Crit Care
Leisman DE, Handisides DR, Busse LW, Chappell MC, Chawla LS, Filbin MR, Goldberg MB, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Adams CD, Hodges TN, Bellomo R, ATHOS-3 Investigators.   +14 more
europepmc   +1 more source